Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

Inclusion Criteria: Women and men, 18-70 years old Healthy patients at the time of enrollment to the study (without active upper respiratory tract infection) Presence of 2 or more episodes of upper respiratory tract infections or >=2 episodes of cold during the year Patients with chronic upper respiratory tract diseases including bronchial asthma Signed informed consent Women: contraception or postmenopausal age Exclusion Criteria: Intake of supplements containing plant extracts, polyphenols or anthocyanins for the 3 months prior to the study initiation Acute inflammation Oral immunosuppressive drugs Steroid, anti-allergic drugs in exacerbations of chronic disease at least 2 months from the start of study participation Antibiotic therapy 1 month prior to study initiation Participation in another clinical trial; Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukaemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplantation; Hypersensitivity/allergy to any of the ingredients of the product, allergy to plants of the Asteraceae family (e.g. chamomile, calendula); Women who are pregnant or planning to become pregnant during the study period;